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Objectives
IVAN and TANDEM are factorial randomised con-
trolled trials (RCTs) of different treatment regimens for
wet AMD, involving off-label use of bevacizumab. Safety
data are being collected but, given follow-up visits every
4-8 weeks for up to 3 years and verbatim reporting, are
difficult to collate. We have developed a database solu-
tion for the TANDEM trial to minimise duplicate
adverse events or events without resolution dates, based
on lessons learnt in the IVAN trial.
Methods
Duplicate reporting of events can arise over multiple
visits for several reasons, for example:
￿ different verbatim reporting (or typographic errors)
of the same event;
￿ e v o l u t i o no fa ne v e n tt h r o u g hs t a g e so fs y m p t o m ,
investigation, diagnosis, treatment;
￿ ongoing events may not be reviewed at every visit
and resolution dates may be missed; if the data record
for such an event is incomplete over time, it is impossi-
ble to know whether a subsequent report describes the
original event or a recurrence.
Results
The database solution has the following features:
￿ coded categories to match most common adverse
events and mapped to MedDRA preferred terms, with
an option to classify as ‘serious’, with reason;
￿‘ other’ category;
￿ optional free-text qualification field for any event.
‘Other’ events will be reviewed regularly and addi-
tional categories added for common events not covered
by the existing codes.
After the first trial visit, a customised adverse event
data form is printed from the trial database in advance
of interviewing the participant. The top half of the form
requires information about ongoing events to be
updated, allowing evolution of an event to be described.
The bottom half of the form allows new events to be
documented using the coded categories and qualification
field. Failure to update an ongoing event generates an
automatic data validation query.
Conclusions
This solution provides complete transparency of adverse
event reporting and real-time coding. It requires
ongoing events to be updated and minimises the pro-
blems created by free-text reporting.
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